PBYI Earnings

PBYI reported its earnings on 2026-05-07, showcasing a revenue of 44.80M against an estimate of 39.22M, resulting in a 14.23% surprise. The EPS was -0.07, surpassing the expected -0.17 by 58.82%. The stock experienced a 3.17% price change on the earnings day and a -1.24% change over the next five days, reflecting market reactions to the results.

Following PBYI's earnings announcement on 2026-05-07, the stock price moved by 3.17% on the day of the release. Over the subsequent five days, it saw a -1.24% change. Historically, PBYI's stock price tends to shift by an average of 0.69% in the 10 days leading up to earnings and 5.65% in the 10 days following, providing insight into potential market.

For 2026/Q2, analysts estimate PBYI's annual revenue to reach 55.00M, while the EPS is projected at . These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between PBYI's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, PBYI's stock price typically moves by 0.69% in the 10 days before its earnings and 5.65% in the 10 days after. For the upcoming 2026/Q2 earnings, analysts expect an EPS of and revenue of 55.00M.

The earnings call reveals declining sales and financial performance, with a significant drop in LYNX product sales and overall revenue. Increased R&D expenses and cash burn raise concerns about financial health. Despite management's commitment to advancing clinical trials, regulatory risks and reliance on specialty distributors pose challenges. The Q&A session did not reveal any positive surprises. The negative sentiment is reinforced by the lack of new partnerships or optimistic guidance, leading to a predicted stock price movement in the negative range of -2% to -8%.